Apellis Pharmaceuticals (APLS) PT Lowered to $61 at BofA Securities
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $61.00 (from $66.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
